Abbott Vascular (Abbott) announced the availability of its next-generation XIENCE PRIME Everolimus Eluting Coronary Stent System for the treatment of coronary artery disease. XIENCE PRIME, which received CE Mark in June 2009, offers a novel stent design and a delivery system designed for greater flexibility and enhanced deliverability. XIENCE PRIME is now widely available in Europe and in select countries throughout Asia-Pacific and Latin America.
Abbott’s XIENCE PRIME is an improvement in design, deliverability and conformability, all of which can be distinctly observed during coronary stent procedures, in both everyday and complex lesions, said Antonio Bartorelli, M.D., director of the Interventional cardiology department of the centro cardiologico monzino, university of Milan, Italy. XIENCE PRIME is designed to be easily deliverable even in complex cases and very long lesions.
XIENCE PRIME utilizes the same well-studied drug and proven biocompatible polymer as Abbott’s XIENCE V Everolimus Eluting Coronary Stent System. XIENCE PRIME is based upon the well-tested design used in the MULTI-LINK VISION family of stents.
XIENCE PRIME leverages the superior outcomes from the extensive body of clinical evidence from the SPIRIT family of clinical trials, and offers design and delivery system properties that make it even easier for a physician to appropriately reach and treat a lesion, said Patrick Serruys, M.D., Ph.D., professor of interventional cardiology at the Thoraxcenter, erasmus university hospital, Rotterdam, the Netherlands. The XIENCE PRIME stent is designed to improve stent deliverability, minimize vessel injury and provide easy access to lesions in complex anatomy.
XIENCE PRIME uses cobalt chromium technology, and has one of the thinnest drug eluting stent struts available, while maintaining strength to support the vessel. It provides visibility under X-ray during the stent implantation procedure. XIENCE PRIME is available in a broad size matrix, including XIENCE PRIME SV for small vessels and XIENCE PRIME LL for long lesions.
XIENCE PRIME reflects Abbott’s commitment to innovation, and based on the positive physician feedback we’ve received from our post-market evaluations, XIENCE PRIME is poised to become the market-leading drug eluting stent across Europe, said Robert Hance, senior vice president, vascular, Abbott.